FDA Brief

Warning letters Drugs

FDA warning letter to

Evolved Ayurvedic Discoveries, Inc./BioCBDPlus

High riskIssued Feb 11, 2021Posted Feb 16, 2021Center for Drug Evaluation and Research | CDER

FDA warned BioCBDPlus that its CBD topicals and vape are unapproved new drugs sold with disease and COVID-19 claims.

What happened

FDA reviewed www.biocbdplus.com from August through October 2020 and also reviewed the company’s Facebook and Instagram pages. FDA found that the website took orders for BioCBD+ products and made claims that they mitigate, prevent, treat, diagnose, or cure diseases, including COVID-19. FDA also said BioCBD+ Total Body Care is labeled as a dietary supplement even though FDA has concluded CBD products are excluded from that definition.

What FDA found

  1. The products are unapproved new drugs because they are not generally recognized as safe and effective for their claimed uses and have no FDA-approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. The products are misbranded because their labeling lacks adequate directions for use for conditions a layperson cannot safely self-diagnose or treat.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5
  3. BioCBD+ Total Body Care cannot be a dietary supplement because FDA has concluded CBD products are excluded from that definition.

    FD&C Act sections 201(ff)(3)(B)(i)-(ii), 21 U.S.C. 321(ff)(3)(B)(i)-(ii)
  4. Website and social media claims that the products treat or prevent diseases such as autism, PTSD, depression, and COVID-19 establish that they are intended as drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  5. The products are new drugs because they are not generally recognized as safe and effective for the uses claimed.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  6. Selling these misbranded drugs across state lines is a prohibited act.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA tells the company to notify it in writing within fifteen working days of receipt of the letter about steps taken to correct the violations, explain how recurrence will be prevented, and include related documentation; if it cannot finish in that time, it must state why and give a completion date.

Who should pay attention

  • CBD and hemp product sellers
  • dietary supplement brands considering CBD
  • online retailers and social media marketers of CBD vapes and topicals

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk